Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $655 | $423 | $476 | $683 |
| - Cash | $83 | $98 | $156 | $60 |
| + Debt | $2 | $4 | $5 | $0 |
| Enterprise Value | $574 | $328 | $326 | $624 |
| Revenue | $0 | $0 | $0 | $19 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | $0 | $0 | $19 |
| % Margin | – | – | – | 100% |
| EBITDA | -$167 | -$190 | -$132 | -$68 |
| % Margin | – | – | – | -358.4% |
| Net Income | -$167 | -$153 | $111 | -$66 |
| % Margin | – | – | – | -346.1% |
| EPS Diluted | -3.11 | -3.69 | 2.38 | -1.48 |
| % Growth | 15.7% | -255% | 260.8% | – |
| Operating Cash Flow | -$145 | -$134 | -$127 | -$43 |
| Capital Expenditures | $0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$145 | -$134 | -$128 | -$44 |